Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.

about

Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.

Item

http://www.wikidata.org/entity/Q35995868

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@ast

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@en

type

Item

label

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@ast

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@en

prefLabel

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@ast

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@en

P1476

Sequential irinotecan hydrochl ...... c cancer: A feasibility study.

@en

P2093

Atsushi Ishiguro

http://www.w3.org/2001/XMLSchema#string

Hiroshi Tohno

http://www.w3.org/2001/XMLSchema#string

Jugoh Itoh

http://www.w3.org/2001/XMLSchema#string

Satoshi Tanaka

http://www.w3.org/2001/XMLSchema#string

Shinsaku Fukuda

http://www.w3.org/2001/XMLSchema#string

Soh Saitoh

http://www.w3.org/2001/XMLSchema#string

Takenori Takahata

http://www.w3.org/2001/XMLSchema#string

Taroh Satoh

http://www.w3.org/2001/XMLSchema#string

Yasuo Saijo

http://www.w3.org/2001/XMLSchema#string

Yoshifumi Matsumoto

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.

Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.

Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.

Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.

Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.

Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

P304

89-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2011.435

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228082957

http://www.w3.org/2001/XMLSchema#string

P698

22740861

http://www.w3.org/2001/XMLSchema#string

P932

3362594

http://www.w3.org/2001/XMLSchema#string